Compare ARK Genomic Revolution ETF (ARKG) vs Raytheon Technologies Corp (RTX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ARK Genomic Revolution ETF vs Raytheon Technologies Corp — how do they compare? ARK Genomic Revolution ETF trades at $41.25, while Raytheon Technologies Corp trades at $195.88 (market cap $263.86B). The key difference: Raytheon Technologies Corp pays a 1.49% dividend while ARK Genomic Revolution ETF pays none, and ARK Genomic Revolution ETF is trading nearer its 52-week high, Raytheon Technologies Corp nearer its low. Which is the better fit depends on your goals.
| ARKG | RTX | |
|---|---|---|
Sector | Sector/Thematic | Industrials |
52-Week High | $43.57 | $212.16 |
52-Week Low | $23.09 | $146.87 |
Market Cap | — | $263.86B |
Enterprise Value | — | $295.97B |
Dividend Yield | — | 1.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ARKG trades at $41.32, down 3.91% today, with a bullish technical signal driven by moving averages. Recent news highlights biotech ETF strength in June 2026, fueled by strong earnings, M&A activity, and AI-driven drug discovery optimism. Key support lies at $40, with resistance at $44.
The outlook remains positive given sector tailwinds, but risks include regulatory hurdles and market volatility. Investor sentiment is buoyed by industry growth catalysts, though selective investment approaches are noted by analysts.
RTX trades at $195.93, up 0.37% today, with a bullish technical signal and strong analyst support. Recent earnings beats, including Q1 2026 EPS of $1.78 versus $1.51 expected, highlight robust operational performance. Revenue grew to $88.60 billion in 2025, with net income margin improving to 8.03%. The company secured a $515 million U.S. Navy contract for SPY-6 radars (PRNewsWire, 2026-06-03), reinforcing its defense segment strength.
The outlook is positive, driven by defense contract wins and commercial aerospace recovery, but risks include debt levels and geopolitical uncertainties. With a consensus price target of $213.00 (18 buy, 8 hold, 0 sell), the stock offers potential upside, though valuation multiples like a P/E of 36.76 warrant monitoring amid interest rate sensitivity.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ARK Genomic Revolution ETF
ARKG is an actively managed ETF that invests in the genomic revolution. It focuses on companies leading in gene editing, CRISPR technology, therapeutics, and molecular diagnostics, including firms like CRISPR Therapeutics and Tempus AI.
Read more on ARKG →About Raytheon Technologies Corp
Raytheon Technologies is a diversified aerospace and defense industrial company formed from the merger of United Technologies and Raytheon, with roughly equal exposure as a supplier to commercial aerospace manufactures and to the defense market as a prime and subprime contractor.
Read more on RTX →
